SCHEMBL24310040

SCHEMBL24310040

CCc1c(Cl)nc(NS(=O)(=O)c2ccccc2)nc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
KDM4E B2RXH2 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PKM P14618 1/20 0.49
ATM Q13315 1/20 0.48
SLC40A1 Q9NP59 2/20 0.47
PIK3CG P48736 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45
MAPT P10636 1/20 0.45
LMNA P02545 1/20 0.45
EDNRB P24530 1/20 0.44
EDNRA P25101 1/20 0.44
IL1RN P18510 1/20 0.44
KEAP1 Q14145 1/20 0.44
ERAP1 Q9NZ08 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309401 0.84 TSHR (0.66) TSHRKDM4ENPSR1RXFP1GAA
SCHEMBL24310041 0.81 TSHR (0.58) TSHRKDM4ENPSR1GAASMN1; SMN2
SCHEMBL24309338 0.80 TSHR (0.60) TSHRKDM4ENPSR1RXFP1GAA
SCHEMBL24309417 0.80 ALDH1A1 (0.46) TSHRALDH1A1
SCHEMBL26868831 0.79 LMNA (0.57) KDM4EALDH1A1MAPTLMNAEDNRB
SCHEMBL10643363 0.78 TSHR (0.62) TSHRKDM4ENPSR1RXFP1GAA
SCHEMBL29516515 0.78 KDM4E (0.59) TSHRKDM4ENPSR1RXFP1GAA
SCHEMBL24287271 0.78 KDM4E (0.59) TSHRKDM4ENPSR1RXFP1GAA
SCHEMBL24309471 0.77 TSHR (0.65) TSHRKDM4ENPSR1RXFP1GAA
SCHEMBL24309501 0.76 MALT1 (0.37) SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B TSHR 1755/4885KDM4E 4141/4885NPSR1 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.